References
- Ambrosioni E. Pharmacoeconomics of hypertension management. The place of combination therapy. PharmacoEconomics 19(4), 337–347 (2001).
- •Presents a comprehensive review of the CE of antihypertensive treatments.
- JNC VI. The sixth report of the National Committee on the detection, evaluation and treatment of high blood pressure UNC Arrh. Inter Med. 157,2413–2446 (1997).
- Guidelines sub-committee of the World Health Organization. World Health Organization — International society of hypertension guidelines for the management of hypertension. J. Hypertens. 17, 151–158 (1999).
- Canadian Hypertension Recommendations Working Group. The 2001 Canadian Hypertension Recommendations — what's new and what's old but still important. Canadian Hypertension Society, Canada (2001).
- Ramsey LE, Williams B, Johnston DG et al Guidelines for the management of hypertension: report of the third working party of the British Hypertension Society. J. Hum. Hypertens. 13, 569–592 (1999).
- Burt VL, Wheltin P, Roccella EJ et at Prevalence of hypertension in the US adult population. Hypertension 25 (3), 305–313 (1995).
- Wolf HK, Tuomilehto J, Kuulasmaa K, Domarkiene S, Cepatis Z. Blood pressure levels in the 41 populations of the WHO MONICA project. j Hum. Hypertens. 11, 733–742 (1997).
- Levy D, Larson MG, Vasan RS, Kannel VVB, Ho KK. The progression from hypertension to congestive heart failure. j4 /t4 275(20), 1557–1662 (1996).
- Staessen JA, Thijs L, Fagard R eta]. Predicting cardiovascular risk using conventional vs. ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAIVIA 282(6), 539–546 (1999).
- Perry HM, Davis BR, Price TR etal. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). /A/VIA 284(4), 465–471 (2000).
- Zanchetti A, Hansson L, Daholf B eta]. Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of Hypertension Optimal Treatment Study. HOT study Group. J. Hypertens. 19(6), 1149–1159 (2001).
- Gensini GF, Corradi E Hypertension as a function of age. Ital. Hear t I 1 (Suppl. 2) 23–31 (2000).
- ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxamsin vs. chlorthalidone: the antihypertenisve and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JA/V/A 283(15) 1967–1975 (2000).
- Flack JM, Novikov SV, Ferrario CM. Benefits of adherence to antihypertensive drug therapy. Eur. Heart 17(Suppl. A), 16–20 (1996).
- Kiiskinen U, Vartiainen E, Puska P, Aromaa A. Long-term cost and life-expectancy consequences of hypertension. J. Hypertens. 16, 1103–1112 (1998).
- Hodgson TA, Cai L. Medical care expenditure for hypertension, its complications and its comorbidities. Med. Care 39(6), 599–615 (2001).
- ••Thorough review of the social cost of HYPin the USA.
- Jönsson B. Measurement of health outcome and associated costs in cardiovascular disease. EUE Heart 17(Suppl. A), 2–7 (1996).
- Berto P, Degli Esposti E, Ruffo P, Buda S, Degli Esposti L, Sturani A. The Pandora Project: cost of hypertension from a general practitioner database. Blood Press. 11, 151–156 (2002).
- Degli Esposti E, Berto P, Buda S, DI Nardo AM, Sturani A. The Pandora project: results of Pilot study. Ann. J. Hypertens. 12, 790–796 (1999).
- Cocchi R, Degli Esposti E, Ruffo P, Buda S, Valpiani G, Sturani A. Cardiovascular risk in hypertensive patients: results of the Pandora project. j Nephrol 15, 29–35 (2002).
- •Review of the medical cost of uncontrolled HYP in Italy.
- Goldberg RJ. Disease management and pharmacoeconomics as tools for mass prevention of hypertensive complications. Heart Dis 3,152–156 (2001).
- UK Prospsective Diabetes Study Group. Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with Type 2 diabetes (UKPDS 40). Br. Med. 317,720-726 (1998).
- Elliot W Weir D, Black H. Cost- effectiveness of the lower treatment goal (of JNC VI) for diabetic hypertensive patients. Arch. Intern. Med 160,1277–1283 (2000).
- Coulhoun HM, Dong W Poulter NR. Blood pressure screening, management and control in England: results from the health survey for England 1994.1 Hypertens. 16, 747–752 (1998).
- Ambrosioni E, Leonetti G, Pessina AC, Rappelli A, Trimarco B, Zanchetti A. Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. J. Hypertens. 18,1691–1699 (2000).
- Kasterinen OH, deBoer A, Paes AH etal. Undertreatment of hypertension in a population-based study in The Netherlands. Hypertens. 16,1371–1387 (1999).
- Marquez-Vidal P, Arveiler D, Amouyel P, Bingham A, Ferrieres J. Sex differences in awareness and control of hypertension in France. Hypertens. 15,1205–1210 (1997).
- Degli Esposti E, Macini Pierluigi, Sturani A, Falasca P, Buda S. Progetto ATLAS: modello per una valutazione globale dell'uso dei farmaci antipertensivi. Management Economia Sanitaria 8 (31), 93–98 (1999).
- •Presents an interesting calculation of the cost of noncompliance in Italy from medical records.
- Paramore LC, Halpern MT, Lapuerta P etal. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am. J. Manag. Care 7(4), 389–398 (2001).
- Lamar Welch VL, Hill MN. Effective strategies for blood pressure control. Cadliol. Clin. 20,321–333 (2002).
- Fender P, Guilhot J, Tilly B, Salanave B, Allemand H. Le traitment de l'HTA severe: cout de la prescription et conformite aux recommandations de l'ANAES. Therapie 56,111–118 (2001).
- Degli Esposti E, Sturani A, Degli Esposti L etal. Pharmaco-utilization of antihypertensive drugs: a model of analysis. Intern. J. Clin. Pharmacol The]: 39(6), 251–258 (2001).
- Mancia G, Sega R, Milesi C, Cesana G, Zanchetti A. Blood-pressure control in the hypertensive population. Lancet 349,454–457 (1997).
- Cramer J. Consequences of intermittenttreatment for hypertension: the case of medication compliance and persistence. Am. Man. Care4(11), 1563–1568 (1998).
- ••Comprehensive review on the implicationsof bad compliance and persistence with medication.
- Sanson-Fisher RVV, Clover K. Compliance in the treatment of hypertension. A need for action. ATM I Hypertens. 8(10), 82S-88S (1995).
- Hansson L. 'Why don't you do as I tell you?' Compliance and antihypertensive regimens. biflj Gin. Path. 56(3), 191–196 (2002).
- Flack JM, Doyle J, Casciano P. Arocho R, Casciano J, Gonzalez MA. The health economic impact of failure to reach blood pressure goals. Ann. J. Hypertens. 13,17A-19A (2000).
- Hansson L, Lloyd A, Anderson P, Kopp Z. Excess morbidity and cost of failure to achieve targets for blood pressure control in Europe. Blood Press 11, 35–45 (2002).
- ••Very recent paper on the cost ofuncontrolled HYP in Canada.
- All F, Scott DA, Lloyd A. Cost of uncontrolled hypertension in Canada. Value in Health 5,481 (plus poster) (2002).
- Hansson L, Zanchetti A, Carruthers SG etal, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet351, 1755–1762 (1998).
- Bernard D, Towsend R, Sylvestri M. Health and disease management what is it and where is it going? Am. J. Hypertens. 11, 103S-108S (1998).
- Rudd P, Ahmed S, Zachary V, Barton C, Bounduelle D. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin. Pharmacol Ther. 48,676-685 (1990).
- •Provides an excellent perspective on the use of patient databases in the management of HYP.
Websites
- World Health Organization. Carcliovascular death and disability can be reduced by more than 50 percent. www.who.intimediacentreireleaseilpr83/en/ Accessed October 31,2002.
- American Heart Association. International Cardiovascular Disease Statistics. Biostatistical fact sheet - population. http://americanheart.org/daownloadable/ heart/1023898043312CVD_stats.pdf Accessed November 5,2002.